Aller au contenu principal
2025 article

Combined supplemental oxygen and mandibular advancement device therapy for obstructive sleep apnoea: a randomised controlled trial

7Citations signalées — pas une note de qualité
11Institutions déclarées
2Pays d’affiliation déclarés

Résumé fourni par la source

Background Treatment for obstructive sleep apnoea (OSA) is limited by intolerance to continuous positive airway pressure. While OSA manifests due to both increased pharyngeal collapsibility and ventilatory control instability, randomised trials targeting both components are lacking. We tested whether combining a ventilatory control intervention (supplemental oxygen) with an upper airway mechanical intervention (mandibular advancement device (MAD)) improves treatment efficacy. Methods In a multicentre randomised crossover trial, 41 patients with moderate-to-severe OSA (apnoea–hypopnoea index (AHI) >20 events·h −1 , scored without desaturation criteria) underwent polysomnography with four single-night interventions: oxygen (4 L·min −1 ), MAD, combination therapy and sham (air). Primary analysis compared percent change in AHI from baseline between combination therapy and MAD monotherapy. Secondary outcomes included arousal index and visual analogue scale for sleep quality (VASSQ). Gold standard baseline pathophysiological traits facilitated mechanistic subgroup analysis. Results Of 41 randomised patients (14 females:27 males, median (interquartile range) baseline AHI 49 (29, 62) events·h −1 ), 38 completed all interventions. Compared with sham, AHI was lowered with oxygen (estimate: −33 (95% CI −46, −17)%), MAD (−54 (95% CI −64, −41)%) and the combination (−68 (95% CI −77, −57)%); the combination provided a greater reduction than MAD monotherapy (−14 (95% CI −23, −4)%; p=0.009). The combination also improved AHI per 3% desaturation/arousal criteria (−73 (95% CI −81, −62)% versus sham and −17 (95% CI −25, −7)% versus MAD). The combination improved arousal index (−36 (95% CI −43, −27)% versus sham) and VASSQ (+0.98 (95% CI 0.39, 1.58) versus sham), albeit not significantly beyond MAD alone. Effects were greatest in those with higher loop gain and collapsibility. Conclusion Combining a ventilatory control intervention (supplemental oxygen) with an upper airway intervention (MAD) is a promising approach to markedly attenuate OSA severity beyond that offered by each intervention alone.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Combined supplemental oxygen and mandibular advancement device therapy for obstructive sleep apnoea: a randomised controlled trial
Date Crossref
02/10/2025
Éditeur
European Respiratory Society (ERS)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Obstructive Sleep Apnea ResearchNeuroscience of respiration and sleepTracheal and airway disorders

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.